Which cardiovascular drugs have the strongest clinical evidence of interaction with green tea/EGCG?
Executive summary
Clinical evidence most convincingly links green tea catechins—especially epigallocatechin gallate (EGCG)—to altered pharmacokinetics of a small set of cardiovascular drugs, with the strongest human data for the hydrophilic beta‑blocker nadolol and modest, reproducible reductions in exposure to the statin rosuvastatin; other signals (including ACE inhibitors like lisinopril and anti‑cancer agents such as erlotinib) come from limited trials or case reports and remain of uncertain clinical consequence [1] [2] [3] [4].
1. Nadolol: the clearest human signal for clinically meaningful interaction
Randomized pharmacokinetic studies led by Japanese investigators found that green tea or EGCG‑concentrated extracts significantly reduced plasma concentrations of nadolol, pointing to an inhibition of intestinal absorption as a plausible mechanism and producing effects large enough to worry about loss of beta‑blocker efficacy in real patients [1] [2].
2. Rosuvastatin: consistent but moderate reductions in exposure
A Korean kinetic study using pure crystalline EGCG (300 mg) with rosuvastatin 20 mg showed co‑administration reduced systemic rosuvastatin exposure by about 19%, an effect described as small to moderate and variably affected by transporter gene polymorphisms (OATP2B1) and by whether EGCG was given acutely or after pretreatment [5] [2].
3. Lisinopril and other antihypertensives: suggestive but inconclusive trial data
Investigators have specifically tested lisinopril with EGCG‑enriched preparations because of the large population taking ACE inhibitors and the theoretical transporter/enzyme effects of catechins, but clinical trials to date were small and while they were designed to detect pharmacokinetic changes, the available reporting highlights uncertainty about meaningful effects on lisinopril exposure or outcomes and cannot establish clinical harm or benefit [1] [6].
4. Case reports and oncology parallels: erlotinib and isolated serious signals
Case reports have associated green tea consumption with altered drug levels for non‑cardiac drugs such as erlotinib and these reports have driven broader concern about catechin‑drug interactions; such scattered case evidence supports vigilance but cannot substitute for controlled trials in cardiovascular populations [3].
5. Mechanisms, variability and why some drugs are vulnerable
EGCG and related catechins can inhibit intestinal and hepatic transporters (OATPs, BCRP) and affect metabolic enzymes and P‑glycoprotein in vitro; these mechanistic findings explain why hydrophilic drugs dependent on intestinal uptake (like nadolol) or transporter‑mediated disposition (like rosuvastatin) show the most consistent clinical signal, but interindividual variability and dose/timing of green tea intake produce inconsistent results across studies [2] [7] [4].
6. How strong is the evidence overall and what it means for clinicians
Systematic reviews and recent updates stress that effects observed in human studies are generally mild to moderate with high interindividual variability and that clinical relevance is not established for many drug pairs—the literature therefore supports particular caution with nadolol (clear pharmacokinetic reductions) and attention to rosuvastatin (modest reductions), while recommending further controlled studies for ACE inhibitors, statins broadly, warfarin‑type interactions, and clinical outcome data before making broad practice changes [4] [2] [6].
7. Hidden agendas, limits of the reporting and alternative viewpoints
Much review literature cautions that small trials in healthy volunteers and case reports can overstate risk or fail to reflect typical patient behavior (different doses, chronic vs acute tea ingestion, genetic polymorphisms); industry, supplement proponents, and clinical authors each carry implicit agendas—manufacturers may highlight benefits of EGCG, clinicians and regulators emphasize safety—so conclusions should weigh randomized human pharmacokinetics over in vitro or animal work and acknowledge gaps where clinical outcome studies are lacking [6] [8].